302 related articles for article (PubMed ID: 28181105)
21. Inhibition of Casein kinase-2 induces p53-dependent cell cycle arrest and sensitizes glioblastoma cells to tumor necrosis factor (TNFα)-induced apoptosis through SIRT1 inhibition.
Dixit D; Sharma V; Ghosh S; Mehta VS; Sen E
Cell Death Dis; 2012 Feb; 3(2):e271. PubMed ID: 22318540
[TBL] [Abstract][Full Text] [Related]
22. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.
Siddiqui-Jain A; Drygin D; Streiner N; Chua P; Pierre F; O'Brien SE; Bliesath J; Omori M; Huser N; Ho C; Proffitt C; Schwaebe MK; Ryckman DM; Rice WG; Anderes K
Cancer Res; 2010 Dec; 70(24):10288-98. PubMed ID: 21159648
[TBL] [Abstract][Full Text] [Related]
23. Comparative genomic and genetic analysis of glioblastoma-derived brain tumor-initiating cells and their parent tumors.
Davis B; Shen Y; Poon CC; Luchman HA; Stechishin OD; Pontifex CS; Wu W; Kelly JJ; Blough MD;
Neuro Oncol; 2016 Mar; 18(3):350-60. PubMed ID: 26245525
[TBL] [Abstract][Full Text] [Related]
24. Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma.
Ashizawa T; Miyata H; Iizuka A; Komiyama M; Oshita C; Kume A; Nogami M; Yagoto M; Ito I; Oishi T; Watanabe R; Mitsuya K; Matsuno K; Furuya T; Okawara T; Otsuka M; Ogo N; Asai A; Nakasu Y; Yamaguchi K; Akiyama Y
Int J Oncol; 2013 Jul; 43(1):219-27. PubMed ID: 23612755
[TBL] [Abstract][Full Text] [Related]
25. Synergistic inhibition of tumor growth by combination treatment with drugs against different subpopulations of glioblastoma cells.
Chang CH; Liu WT; Hung HC; Gean CY; Tsai HM; Su CL; Gean PW
BMC Cancer; 2017 Dec; 17(1):905. PubMed ID: 29284440
[TBL] [Abstract][Full Text] [Related]
26. Bmi1 marks intermediate precursors during differentiation of human brain tumor initiating cells.
Venugopal C; Li N; Wang X; Manoranjan B; Hawkins C; Gunnarsson T; Hollenberg R; Klurfan P; Murty N; Kwiecien J; Farrokhyar F; Provias JP; Wynder C; Singh SK
Stem Cell Res; 2012 Mar; 8(2):141-53. PubMed ID: 22265735
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth.
Pozo N; Zahonero C; Fernández P; Liñares JM; Ayuso A; Hagiwara M; Pérez A; Ricoy JR; Hernández-Laín A; Sepúlveda JM; Sánchez-Gómez P
J Clin Invest; 2013 Jun; 123(6):2475-87. PubMed ID: 23635774
[TBL] [Abstract][Full Text] [Related]
28. Influence of Casein kinase II inhibitor CX-4945 on BCL6-mediated apoptotic signaling in B-ALL in vitro and in vivo.
Richter A; Sender S; Lenz A; Schwarz R; Hinz B; Knuebel G; Sekora A; Murua Escobar H; Junghanss C; Roolf C
BMC Cancer; 2020 Mar; 20(1):184. PubMed ID: 32131762
[TBL] [Abstract][Full Text] [Related]
29. Precursor States of Brain Tumor Initiating Cell Lines Are Predictive of Survival in Xenografts and Associated with Glioblastoma Subtypes.
Cusulin C; Chesnelong C; Bose P; Bilenky M; Kopciuk K; Chan JA; Cairncross JG; Jones SJ; Marra MA; Luchman HA; Weiss S
Stem Cell Reports; 2015 Jul; 5(1):1-9. PubMed ID: 26095605
[TBL] [Abstract][Full Text] [Related]
30. Modulation of invasive properties of CD133+ glioblastoma stem cells: a role for MT1-MMP in bioactive lysophospholipid signaling.
Annabi B; Lachambre MP; Plouffe K; Sartelet H; Béliveau R
Mol Carcinog; 2009 Oct; 48(10):910-9. PubMed ID: 19326372
[TBL] [Abstract][Full Text] [Related]
31. Up-Regulation of the Alpha Prime Subunit of Protein Kinase CK2 as a Marker of Fast Proliferation in GL261 Cultured Cells.
Villamañan L; Alcaraz E; Pinna LA; Ruzzene M; Itarte E; Arús C; Plana M; Candiota AP
Pathol Oncol Res; 2019 Oct; 25(4):1659-1663. PubMed ID: 30607803
[TBL] [Abstract][Full Text] [Related]
32. Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells.
Bliesath J; Huser N; Omori M; Bunag D; Proffitt C; Streiner N; Ho C; Siddiqui-Jain A; O'Brien SE; Lim JK; Ryckman DM; Anderes K; Rice WG; Drygin D
Cancer Lett; 2012 Sep; 322(1):113-8. PubMed ID: 22387988
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of casein kinase 2 prevents growth of human osteosarcoma.
Takahashi K; Setoguchi T; Tsuru A; Saitoh Y; Nagano S; Ishidou Y; Maeda S; Furukawa T; Komiya S
Oncol Rep; 2017 Feb; 37(2):1141-1147. PubMed ID: 27959425
[TBL] [Abstract][Full Text] [Related]
34. The role of sphingosine kinase-1 in EGFRvIII-regulated growth and survival of glioblastoma cells.
Estrada-Bernal A; Lawler SE; Nowicki MO; Ray Chaudhury A; Van Brocklyn JR
J Neurooncol; 2011 May; 102(3):353-66. PubMed ID: 20938717
[TBL] [Abstract][Full Text] [Related]
35. Expression of CD133 and CD44 in glioblastoma stem cells correlates with cell proliferation, phenotype stability and intra-tumor heterogeneity.
Brown DV; Filiz G; Daniel PM; Hollande F; Dworkin S; Amiridis S; Kountouri N; Ng W; Morokoff AP; Mantamadiotis T
PLoS One; 2017; 12(2):e0172791. PubMed ID: 28241049
[TBL] [Abstract][Full Text] [Related]
36. CK2 inhibition induced PDK4-AMPK axis regulates metabolic adaptation and survival responses in glioma.
Dixit D; Ahmad F; Ghildiyal R; Joshi SD; Sen E
Exp Cell Res; 2016 May; 344(1):132-142. PubMed ID: 27001465
[TBL] [Abstract][Full Text] [Related]
37. Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth.
Pizzi M; Piazza F; Agostinelli C; Fuligni F; Benvenuti P; Mandato E; Casellato A; Rugge M; Semenzato G; Pileri SA
Oncotarget; 2015 Mar; 6(9):6544-52. PubMed ID: 25788269
[TBL] [Abstract][Full Text] [Related]
38. Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens.
Kelly JJ; Stechishin O; Chojnacki A; Lun X; Sun B; Senger DL; Forsyth P; Auer RN; Dunn JF; Cairncross JG; Parney IF; Weiss S
Stem Cells; 2009 Aug; 27(8):1722-33. PubMed ID: 19544433
[TBL] [Abstract][Full Text] [Related]
39. Tropism of mesenchymal stem cell toward CD133
Pavon LF; Sibov TT; de Souza AV; da Cruz EF; Malheiros SMF; Cabral FR; de Souza JG; Boufleur P; de Oliveira DM; de Toledo SRC; Marti LC; Malheiros JM; Paiva FF; Tannús A; de Oliveira SM; Chudzinski-Tavassi AM; de Paiva Neto MA; Cavalheiro S
Stem Cell Res Ther; 2018 Nov; 9(1):310. PubMed ID: 30413179
[TBL] [Abstract][Full Text] [Related]
40. ShRNA-based POLD2 expression knockdown sensitizes glioblastoma to DNA-Damaging therapeutics.
Xu Q; Hu C; Zhu Y; Wang K; Lal B; Li L; Tang J; Wei S; Huang G; Xia S; Lv S; Laterra J; Jiang Y; Li Y
Cancer Lett; 2020 Jul; 482():126-135. PubMed ID: 31954770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]